Shares of Tempus AI Inc. (NASDAQ:TEM) climbed 3% on Friday morning after the company announced an expanded multi-year collaboration with Gilead Sciences Inc. (NASDAQ:GILD), aimed at supporting the development of Gilead’s oncology pipeline.
The new agreement grants Gilead enterprise-wide access to Tempus’ AI-powered Lens platform, which offers expanded datasets across various disease areas along with dedicated analytical support. Gilead has already been utilizing Tempus’ anonymized multimodal data for oncology research, including applications in clinical trial design, indication selection, biomarker development, health outcomes analysis, and real-world evidence generation.
As part of the enhanced partnership, Gilead will use Tempus’ multimodal data resources to generate insights intended to guide clinical decision-making in cancer care.
“By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights,” said Ryan Fukushima, CEO of Tempus Data & Apps. “We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights.”
Tempus AI is a technology firm focused on applying artificial intelligence to advance precision medicine through its data and analytics platforms.